Merck 3Q Revenues: $10.5 billion (+5%) 3Q Earnings: $2.2 billion (+19%) YTD Revenues: $29.7 billion (+1%) YTD Earnings: $4.5 billion (+30%) Comments: Pharmaceutical sales were up 6% in the quarter to $9.4 billion, reflecting higher vaccines sales, oncology, cardiovascular franchise sales and hospital acute care. Sales of GARDASIL 9 and GARDASIL were up 38% to $860 million and PROQUAD / M-M-R II sales were up 27% to $496 million, driven by the timing of sales activity in the third ...